Search

everythinglearnresearchcommunity

for

Search:↓

The Swedish neonatal screening program effectively detects PKU, galactosaemia, and biotinidase deficiency with low false positives.

Sonidegib effectively treated basal cell carcinoma in a patient with lupus without worsening lupus symptoms.

The new nasal gel for schizophrenia improved drug absorption and brain effects in rats.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.

Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.

Nanoporous silica entrapped lipid-drug complexes significantly improve the solubility and absorption of drugs that don't dissolve well in water.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Blocking YAP/TAZ could be a new way to treat skin cancer.

The boy's severe skin disorder is caused by two new mutations in his TGM1 gene.

The hydrogel speeds up diabetic wound healing by adapting to glucose levels and releasing insulin.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Guselkumab significantly improves quality of life for people with moderate to severe psoriasis.

Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.

GLP-1 agonists may help treat certain skin conditions.

Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.

Elagolix did not effectively treat polycystic ovary syndrome.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.